<DOC>
	<DOCNO>NCT00789841</DOCNO>
	<brief_summary>We study total gastrointestinal transit time ( GITT ) , gastric empty small intestine motility NET patient treat somatostatin analogue compare healthy subject . For use radio-opaque marker newly develop Motility Tracking System ( MTS ) . Hypothesis : Patients NET carcinoid syndrome decrease GITT , gastric empty small bowel transit time increase phase III MMC activity compare healthy subject . Treatment somatostatin analogue increase transit time decrease phase III MMC activity improve clinical symptom .</brief_summary>
	<brief_title>Gastrointestinal Motility Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>NET confirm histology Diarrhea , ( least 3 loose watery bowel movement per day ) part carcinoid syndrome . Newly refer patient without previous somatostatin analogue treatment NET patient pause somatostatin analogue treatment due treatment examination . Subjects unable understand information Severe diabetes late complication know metabolic disorder Inflammatory bowel disease Known clinically significant stenosis bowel Bile acid malabsorption due intestinal surgery Small bowl bacterial overgrowth</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Carcinoid syndrome</keyword>
	<keyword>Motility</keyword>
	<keyword>Transit time</keyword>
</DOC>